Dante Durand
Psychiatry · Miami, FLNPI 1093754335
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,652 of the $31,914 with a category attached, or 74.1%. Otsuka Pharmaceutical Development & Commercialization, Inc. accounts for 64.9% of it on its own, with 11 other manufacturers making up the rest. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $384.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$21K
- Otsuka America Pharmaceutical, Inc.$5K
- Boehringer Ingelheim$4K
- Neurocrine Biosciences, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$490
- Johnson & Johnson$158
- plus $319 from 6 others
Across 49 payments — averaging $17,192 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$761K
- Roche TCRC, Inc.$52K
- Janssen Research & Development, LLC$29K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$282
What the payments were for
- Speaking & faculty fees$23,65274%
- Travel & lodging$4,35414%
- Food & beverage$3,90212%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 30 | $20,706 |
| Otsuka America Pharmaceutical, Inc. | 9 | $4,585 |
| Boehringer Ingelheim | 13 | $3,582 |
| Neurocrine Biosciences, Inc. | 13 | $2,075 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $490 |
| Johnson & Johnson(2 entities) | 2 | $158 |
| E.r. Squibb & Sons, L.L.C. | 1 | $105 |
| Indivior Inc. | 2 | $79 |
| Teva Pharmaceuticals USA, Inc. | 2 | $52 |
| Alkermes, Inc. | 2 | $34 |
| Pear Therapeutics (US), Inc. | 1 | $31 |
| Axsome Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$451
- RISPERDAL$120
- INVEGA SUSTENNA$120
- REJOYN$120
- CAPLYTA$106
- COBENFY$105
How this compares
$31,914 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clonazepam | 13 | $127 |
| Escitalopram Oxalate | 14 | $48 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Miami
- Kenny PerezMiami$453K
- Erik CabreraMiami$357K
- Miguel FloresMiami$176K
- Pedro RodriguezMiami$96K
- John NewcomerMiami$96K
- Patricia JunqueraMiami$80K
- Marc AgroninMiami$66K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.